J. Neyts

The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model

This paper evaluates a triple antiviral combination's efficacy against coronavirus in cell cultures and a hamster model, finding enhanced antiviral effects even with suboptimal doses.

Proliferative cell targeting and epithelial cell turnover fuels hepatitis E virus replication in human intestinal enteroids

This study establishes an HEV-HIE model showing HEV replication in intestinal epithelial cells, with proliferative cells being the main targets, suggesting the gut as an HEV reservoir.

Yeast-based production platform for potent and stable heavy chain-only antibodies

This paper presents a yeast-based platform for producing stable and potent heavy chain-only antibodies, demonstrating its effectiveness with an anti-SARS-CoV-2 example.

ACE2 mimetic antibody potently neutralizes all SARS-CoV-2 variants and fully protects in XBB.1.5 challenged monkeys

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

The paper identifies ultrapotent SARS-CoV-2-neutralizing nanobodies that bind a conserved epitope on the spike protein, showing therapeutic efficacy in hamsters.

Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection

This study examines the genetic effects of effective and suboptimal dosing of mutagenic drugs on SARS-CoV-2 in hamsters, finding dose-dependent mutational load and no drug resistance.

Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge

This study develops a dual-target vaccine against Ebola and yellow fever viruses, showing it protects mice against both pathogens with a single dose.

Combination of the parent analogue of Remdesivir (GS-441524) and Molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters

This study shows that combining GS-441524 and molnupiravir significantly reduces SARS-CoV-2 viral load in infected Syrian hamsters.

Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in Syrian hamsters

This study shows that nirmatrelvir-resistant SARS-CoV-2 variants replicate and transmit efficiently in Syrian hamsters, highlighting the need for combination therapies to prevent resistance spread.

The dissemination of Rift Valley fever virus to the eye and sensory neurons of zebrafish larvae is stat1 dependent.

This study shows that RVFV spreads to the eye and sensory neurons in zebrafish larvae in a stat1-dependent manner, causing blindness through direct damage rather than brain infection.

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir

This paper identifies three substitutions in SARS-CoV-2 3CLpro that confer resistance to nirmatrelvir and other 3CLpro inhibitors in vitro.

A SCID mouse model to evaluate the efficacy of antivirals against SARS-CoV-2 infection

This paper establishes a SCID mouse model infected with the SARS-CoV-2 beta B.1.351 variant to evaluate antiviral efficacy, showing significant reduction in viral load with Molnupiravir and Nirmatrelvir.

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties

This paper identifies a potent human monoclonal antibody, P2G3, that neutralizes multiple SARS-CoV-2 variants including Omicron, and demonstrates its protective efficacy in a monkey model.

Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model

This study shows that Ivermectin does not reduce SARS-CoV-2 lung viral load or improve lung pathology in Syrian hamsters and does not enhance Molnupiravir's effect.

Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures

The paper develops a high-throughput screening assay to evaluate 5676 phase 1 compounds for in vitro anti-SARS-CoV-2 activity, identifying eight candidates but finding only remdesivir suitable for further clinical development.

Biodistribution and Environmental Safety of a Live-attenuated YF17D-vectored SARS-CoV-2 Vaccine Candidate

This study evaluates the safety and biodistribution of a YF17D-vectored SARS-CoV-2 vaccine candidate in hamsters, showing improved safety compared to parental YF17D.

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

The paper evaluates the antiviral activity of remdesivir, molnupiravir, and nirmatrelvir against SARS-CoV-2 variants, finding they remain effective.

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

This study shows that the omicron SARS-CoV-2 variant infects Syrian hamsters with significantly lower viral loads in the lungs compared to the D614G strain, with no detectable infectious virus.

Anti-SARS-CoV-2 human antibodies retaining neutralizing activity against SARS-CoV-2 B.1.1.529 (omicron)

The paper evaluates a panel of anti-SARS-CoV-2 monoclonal antibodies for neutralizing activity against SARS-CoV-2 delta and omicron variants, finding three mAbs retain activity, with mAb 3B8 showing potent neutralization against both.

A high-throughput neutralization assay for yellow fever serodiagnostics

This paper develops a high-throughput fluorescence-based assay (SNTFLUO) for detecting yellow fever neutralizing antibodies, validated against WHO standards and applicable for differential diagnostics.

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model

The paper identifies potent anti-SARS-CoV-2 mAbs that cure infection in hamsters and demonstrates gene-based delivery for in vivo protection against variants.

Updated vaccine protects from infection with SARS-CoV-2 variants, prevents transmission and is immunogenic against Omicron in hamsters

This study shows an updated vaccine candidate provides full protection against multiple SARS-CoV-2 variants, prevents transmission, and induces neutralizing antibodies against Omicron in hamsters.

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.

Spatial proteogenomics reveals distinct and evolutionarily-conserved hepatic macrophage niches

This study creates a spatial proteogenomic atlas of the liver across species, identifying conserved macrophage niches and their regulatory mechanisms.

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry

This study identifies a broadly neutralizing antibody against sarbecoviruses that targets the ACE2 binding site and shows high resistance to escape mutations.

The Urtica Dioica Agglutinin Prevents Rabies Virus Infection in a Muscle Explant Model

The paper evaluates lectins for anti-rabies virus activity, identifies Urtica dioica Agglutinin (UDA) as effective in preventing RABV infection in a muscle explant model.

Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen

This study identifies lapatinib, an ErbB inhibitor, as a broad-spectrum antiviral that suppresses SARS-CoV-2 and VEEV replication, inflammation, and lung injury through ErbB-mediated mechanisms.

A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery

This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.